Table IV.
Unadjusted and adjusted prevalence ratios of significant fibrosis (n=557)a
| Unadjusted PR | 95% CI | Adjusted PR* | 95% CI | |
|---|---|---|---|---|
| Age (per 10 years) | 1.25 | - | 1.43 | 0.68 - 1.58 |
| Years of injection drug use | 0.97 - 1.08 | |||
| ≤ 1 | 1 | - | 1 | - |
| 1-5 | 1.75 | 0.22 - 13.8 | 1.41 | 0.18 - 10.8 |
| 6-10 | 2.29 | 0.30 - 17.6 | 1.38 | 0.28 - 16.9 |
| >10 | 4.11 | 0.57 - 29.6 | 2.18 | 0.28 - 16.9 |
| HIV/HCV | ||||
| HIV/HCV uninfected | 1 | 1 | ||
| HIV mono-infected | 0.73 | 0.10 - 5.59 | 1.17 | 0.15 - 8.96 |
| HCV mono-infected | 3.10 | 1.27 - 7.58 | 3.34 | 1.23 - 9.07 |
| HIV/HCV co-infected | 3.35 | 1.27 - 8.81 | 3.92 | 1.29 - 11.9 |
| Chronic HBV infection | 1.50 | 0.69 - 3.27 | 1.49 | 0.69 - 3.22 |
| % visits heavy alcohol use reported | 4.04 | 1.45 - 11.29 | 6.62 | 2.68 - 16.3 |
| % visits daily marijuana use reported | 0.42 | 0.19 - 0.94 | 0.37 | 0.16 - 0.83 |
| % visits heroin injection | 2.03 | 0.49 - 8.38 | ||
| % visits buprenorphine injection | 0.87 | 0.05 - 14.3 | ||
| % visits non-buprenorphine pharmaceutical drug use | 5.13 | 1.35 - 19.5 | 2.15 | 0.59 - 7.94 |
Prevalence ratios estimated using Poisson regression with robust variance estimation; Adjusted for age, years of injection drug use, HIV/ HCV status, HBsAg status, % of visits where heavy alcohol use, marijuana use, and other non-buprenporphine pharmaceutical drug use was reported. % visits daily marijuana use reported was calculated by dividing the number of follow up of visits where daily marijuana use was reported, divided by the total number of follow up visits that each participant attended. % visits heavy alcohol use reported, % visits heroin injection, % visits buprenorphine injection and % visits other non-buprenorphine pharmaceutical drug use where calculated in a similar fashion. PR, prevalence ratio; 95% CI, 95% confidence interval; HIV, human immunodeficiency virus; HCV, hepatitis C virus; heavy alcohol use was defined as drinking alcohol at least 3 days a week